Our findings suggest that while both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2- breast cancer, nuances in their impact, particularly on the HER2-enriched signature, warrant further investigation. This evidence concerns the gene ERBB2 and breast cancer.